Yahoo
ASX - Delayed Quote AUD

Orthocell Limited (OCC.AX)

0.5500 +0.0150 (+2.80%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for OCC.AX
  • Previous Close 0.5350
  • Open 0.5350
  • Bid 0.5400 x --
  • Ask 0.5500 x --
  • Day's Range 0.5300 - 0.5550
  • 52 Week Range 0.4900 - 1.2550
  • Volume 92,728
  • Avg. Volume 369,683
  • Market Cap (intraday) 149.817M
  • Beta (5Y Monthly) -0.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 0.90

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

orthocell.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

OCC.AX
49.31%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

OCC.AX
52.79%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

OCC.AX
52.78%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

OCC.AX
2.80%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

0.65
0.90 Average
0.5500 Current
1.15 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -121.98%

  • Return on Assets (ttm)

    -25.52%

  • Return on Equity (ttm)

    -56.82%

  • Revenue (ttm)

    11.41M

  • Net Income Avi to Common (ttm)

    -13.91M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    43.95M

  • Total Debt/Equity (mrq)

    2.82%

  • Levered Free Cash Flow (ttm)

    -9.81M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: